Articles

MacuSight has announced positive interim data from a Phase I study of its proprietary formulation of sirolimus (originally known as rapamycin) for the treatment of chronic, clinically significant diabetic macular oedema (DME).

The corneal stroma has the ability to clear microorganisms introduced during LASIK.

Repeat injections of bevacizumab are well tolerated; Bevacizumab reduces DME in the short-term; Unveiling a new clinical entity; Pupil dilation linked to glaucoma progression; Glaucoma scales fail to impress; New glaucoma progression predictors; Central vision loss & trabeculectomy; UK optometrists given prescribing powers; Higher retinal re-attachment success in patients with complete PVD; Every other year screening for retinopathy; A new approach for analysing patient compliance.

Persistent placoid maculopathy has features resembling macular serpiginous choroiditis but differs in its clinical course and effect on visual acuity.

Lower systolic perfusion pressure, lower systolic blood pressure and cardiovascular disease history are all predictors of glaucoma.

The desired refractive outcome is approximately 2 D by age two and 1 to 2 D by age three, reflecting the fact that the majority of growth of the eye has occurred by this age

We speak with Ivo Kocur of the World Health Organization who tells us how Vision 2020 is helping to reduce avoidable blindness in children around the world.

In patients with advanced visual field loss undergoing trabeculectomy with mitomycin C, there is a risk of severe loss of central vision.

...The eyes were generally not inflamed and achieved their maximum visual potential in a matter of weeks as opposed to the many months required for rehabilitation following a corneal transplant

Optometrists in the UK will soon be given the power to prescribe drugs for conditions such as dry eye.

In patients with open-angle glaucoma (OAG), the increase in intraocular pressure (IOP) caused by pharmacological pupillary dilation is related to the likelihood of future progression of glaucoma.

Repeat intravitreal injections of bevacizumab (off-label Avastin) for diseases such as proliferative diabetic retinopathy (DR), diabetic macular oedema (DME), retinal vein occlusions and choroidal neovascularization (CNV) appear to be safe and well tolerated.

Subspecialty training courses in ophthalmology are often subject to criticism because of the lack of detail that is provided to students wanting to specialise in a particular area.

Carl Zeiss to acquire Acri.Tec; B&L and Alcon settle dispute amicably; Alcon amends tender offer for Wavelight.

Carl Zeiss Meditec has announced that it intends to acquire Acri.Tec.

Every other year screening for diabetic eye disease appears to be both safe and effective in patients with diabetes without retinopathy.

The presence of a complete posterior vitreous detachment (PVD) may be associated with an increased likelihood for primary anatomic success following retinal detachment surgery in phakic eyes.

Welcome to the October issue of OTE and the second anniversary edition of our magazine. Two years ago this month saw the first issue of OTE hit desks across Europe.

Bausch & Lomb and Alcon have settled a lawsuit that was filed recently regarding Alcon's promotional claims about Bausch & Lomb's ReNu MultiPlus solution.

A gap analysis approach may be preferable to Kaplan-Meier survival curves for analysing patient persistence with prescribed medications.

Intravitreal bevacizumab can reduce diabetic macular oedema (DME) in some eyes, but a Phase III trial is required to determine whether the treatment is beneficial in the long-term.

Read Ophthalmology Times Europe's extensive coverage from the 2007 annual meeting in Stockholm, Sweden.

The Visual Impairment Instrument (IVI) and the Glaucoma Symptom Scale (GSS) are suboptimal scales for assessing patients with glaucoma but relatively good vision.

There is no need for children with lazy eye to wear an eye patch for the whole day, in order to correct their vision, according to report published online by the British Medical Journal.

Regeneron Pharmaceuticals has received a $20 million milestone payment from Bayer HealthCare following dosing of the first patient in a Phase III study of the VEGF Trap-Eye for the treatment of wet age-related macular degeneration (AMD).

Alimera Sciences and pSivida have announced that enrolment has begun for the first human pharmacokinetic study of fluocinolone acetonide (FA) in Medidur, the companies' product for the treatment of diabetic macular oedema (DME).

Ophthotech Corporation has announced deals with two companies to obtain the rights to treatments for age-related macular degeneration (AMD).

The decline in quality of life (Qol) and the increased need for daily living assistance in patients with wet age-related macular degeneration (AMD) substantiates the need for new treatments that can halt disease progression, according to a multi-country study published in the September issue of Archives of Ophthalmology.

Central corneal thickness (CCT) measurements should be included as part of a complete ocular examination, particularly in patients at risk of developing primary open angle glaucoma (POAG), according to a study conducted by the American Academy of Ophthalmology and published in the journal Ophthalmology.

Intravitreal injections for the treatment of retinal diseases, such as neovascular age-related macular degeneration (AMD), could be replaced by a non-invasive gel formulation, applied under the eyelid, according to a presentation made at this month's meeting of the British Royal Pharmaceutical Society in Manchester, UK.